

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): Nabil HANNA

Appl. No.: 09/

Series Code ↑

Filed: April 2, 2001

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

REPLY/AMENDMENT/LETTER

Group Art

1642

Examiner:

L. Helms

Atty. Dkt.

P

0280062

2000-30-0178A

Appln. Title:

Combined Use of Anti-Cytokine
Antibodies or Antagonists and Anti-
CD20 for the Treatment of a B Cell
Lymphoma

Date: April 21, 2003

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated herinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim

- A. ☒ NOT made
B. ☐ Withdrawn
C. ☐ made herewith
D. ☐ made previously

For B & C.
See Required
Separate Paper
(Pat-256)

Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	**minus 0	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	***minus 0	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application) add			+ \$280/\$140 =	+ \$0	104/204
5. Original due Date: March 19, 2003 <input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo) \$110/\$55 = (2 mos) \$410/\$205 = (3 mos) \$930/\$465 = (4 mos) \$1,450/\$725 = (5 mos) \$1,970/\$985 =	+ \$110		115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract			- \$0		
8.			Extension Fee	+ \$110	
9. If Terminal Disclaimer attached, add Rule 20(d) official fee			+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c), add			+ \$180	+ \$0	126
or if Rule 97(d) Request add			+ \$180		126
11. After-Final Request Fee per rules 129(a) and 17(r)			+ \$750/370	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b).....			x \$750/375 ea	+ \$0	149/249
13. Request for Continued Examination (RCE)			+ \$750/375	+ \$0	1179/1279
14. Petition fee for				+ \$0	
15.			TOTAL FEE = \$110		
16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".					
17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.					
18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.					
			PLEASE CHARGE OUR DEP. ACCT		

Our Deposit Account No. 03-3975)

(Our Order No. 037003

0280062

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP

Intellectual Property Group

By Atty: Thomas A. Cawley, Jr.

Reg. No. 40944

Sig:

Fax:

(703) 905-2500

Tel:

(703) 905-2144

P.O. Box 10500
McLean, VA 22102
Tel: (703) 905-2000

Atty/Sec: TACJ/JB/af

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments



USAN

UNITED STATES ADOPTED NAMES COUNCIL

RUTA FREIMANIS, Pharm.D., R.Ph., Secretary
(312) 464-4045

American Medical Association
515 North State Street
Chicago, Illinois 60610


Telefax: 312-464-4184
Telex: 280248 AMA CGO

September 25, 1996

II-64

IDEC Pharmaceuticals Corporation
11011 Torreyana Road
San Diego, CA 92121

Attn: John F. Wood
Regulatory Affairs Associate



Dear Mr. Wood:

It is my pleasure to inform you that the USAN Council adopted **rituximab** as the United States Adopted Name for Idec Pharmaceutical Corporation's antineoplastic monoclonal antibody IDEC-C2B8; IDEC-102.

Enclosed is a copy of the Statement of Adoption on **rituximab**. I plan to schedule publication of this information in the journal of Clinical Pharmacology and Therapeutics unless you request a delay within the next thirty days. Please use the enclosed statement to provide comments or additions. If this information is accurate, and may be published, please initial the statement and return it to me.

Sincerely yours,

Ruta Freimanis, PharmD
Secretary, USAN Council

RF/gat

Enclosure: N96;65